Formulary Search Results for: CALCIUM AND VITAMIN D
10.1.1 Non-steroidal anti-inflammatory drugs - View Category
Restrictions:
Use of MR preparations is restricted. Modified-release preparations of any NSAID should be restricted to patients with early morning stiffness or compliance problems as they encourage regular/higher doses of NSAIDs and do not afford flexibility in reducing the dose.
Prescribing Notes:
In June 2013, the MHRA issued new contraindications and warnings for diclofenac following a review of the cardiovascular risk, which it states is similar to that of the selective COX-2 inhibitors. A summary of the guidance on the MHRA website is available HERE
10.2.2 Skeletal muscle relaxants - View Category
10.2.2 Skeletal muscle relaxants - View Category
9.1.1.2 Parenteral iron - View Category
Restrictions:
Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used is restricted to specialist use only in adults with chronic kidney disease on dialysis.
9.1.1.2 Parenteral iron - View Category
Restrictions:
The treatment of iron deficiency anaemia (diagnosis based on laboratory tests) when oral iron preparations are ineffective or cannot be used is restricted to specialist use.
Prescribing Notes:
These preparations are more expensive than some other IV iron preparations. Use in patients on haemodialysis or use as a bolus injection was not recommended by SMC and remains non-Formulary.
For the relevant SMC advice click here
9.1.1.2 Parenteral iron - View Category
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist use only in accordance with the Prescribing Notes below.
Prescribing Notes:
Formulary indications:
- Treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions when deferoxamine therapy is contraindicated or inadequate
- Treatment of myeloplastic syndrome (MDS) in patients with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk when deferoxamine therapy is contraindicated or inadequate in accordance with regional protocol (in development)
It is not recommended by SMC for:
- Treatment of patients with chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes and is non-Formulary for these indications.
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure. This is the preferred Formulary agent for this indication.
9.1.4 Drugs used in platelet disorders - View Category
Restrictions:
Restricted to specialist use for the following indications:
- The treatment of severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure
- The treatment of primary chronic thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids or immunoglobulins) where patients have severe symptomatic ITP or a high risk of bleeding in accordance with local protocol (in development).